Company Encyclopedia
View More
name
WEIGUANG BIOLOGICAL
002880.SZ
Shenzhen Weiguang Biological Products Co., Ltd. primarily engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous injection freeze-dried, lyophilized human rabies vaccine and human prothrombin complex. Shenzhen Weiguang Biological Products Co., Ltd.
1.565 T
002880.SZMarket value -Rank by Market Cap -/-

Financial Score

09/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking44/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE10.24%B
    • Profit Margin20.06%A
    • Gross Margin40.85%B
  • Growth ScoreC
    • Revenue YoY-2.33%D
    • Net Profit YoY-8.57%C
    • Total Assets YoY7.03%B
    • Net Assets YoY8.46%B
  • Cash ScoreC
    • Cash Flow Margin498.52%C
    • OCF YoY-2.33%D
  • Operating ScoreD
    • Turnover0.35D
  • Debt ScoreB
    • Gearing Ratio30.56%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    WEIGUANG BIOLOGICAL released its performance for the first three quarters, with a net profit attributable to the parent company of 158 million yuan, a year-on-year decrease of 13.60%

    According to the Zhitong Finance APP, WEIGUANG BIOLOGICAL released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 791 million yuan, a year-on-year decrease of 7.40%. The net profit attributable to shareholders of the listed company was 158 million yuan, a year-on-year decrease of 13.60%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 155 million yuan, a year-on-year decrease of 12.67%

    Zhitong·
    SZ
    002880
    -0.19%
    Zhitong·
    SZ
    002880
    -0.19%

    WEIGUANG BIOLOGICAL won an industrial land in Guangming District for 60.4 million yuan

    According to the Zhitong Finance APP, WEIGUANG BIOLOGICAL announced that on September 5, 2025, the company participated in the public listing of the state-owned construction land use rights for the land parcel number A628-0045 held by the Shenzhen Trading Group Co., Ltd. Land and Mining Rights Business Division, successfully obtaining the use rights for the above-mentioned land at a price of 60.4 million yuan, and signed the "Transaction Confirmation." The land is designated for general industrial use, with an area of 69,986.43 square meters

    Zhitong·
    SZ
    002880
    -0.19%
    Zhitong·
    SZ
    002880
    -0.19%

    WEIGUANG BIOLOGICAL released its performance for the first half of the year, with a net profit attributable to the parent company of 108 million yuan, a decrease of 2.02%

    According to the Zhitong Finance APP, WEIGUANG BIOLOGICAL released its semi-annual report for 2025, reporting an operating income of 518 million yuan, a year-on-year decrease of 0.92%. The net profit attributable to shareholders of the listed company was 108 million yuan, a year-on-year decrease of 2.02%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 106 million yuan, a year-on-year decrease of 1.36%. The basic earnings per share were 0.4746 yuan

    Zhitong·
    SZ
    002880
    -0.19%
    Zhitong·
    SZ
    002880
    -0.19%

    WEIGUANG BIOLOGICAL plans to raise no more than 1.5 billion yuan through a private placement for the smart industry base project and to supplement liquidity

    WEIGUANG BIOLOGICAL plans to raise no more than 1.5 billion yuan by issuing A-shares to specific targets. This issuance will be directed at no more than 35 specific targets, with the issuance price set at 80% of the company's average stock trading price. The number of shares issued will not exceed 45.36 million shares, and the raised funds will be used for the smart industry base project and to supplement working capital

    Zhitong·
    SZ
    002880
    -0.19%
    Zhitong·
    SZ
    002880
    -0.19%

    WEIGUANG BIOLOGICAL plans to invest CNY 2.308 billion to build an intelligent industrial base in Guangming District, Shenzhen, to expand production capacity

    WEIGUANG BIOLOGICAL plans to invest CNY 2.308 billion in the Guangming District of Shenzhen to build an intelligent industrial base. The project includes facilities such as dormitories, factories, and warehouses, aimed at meeting the production needs of blood products, with a designed annual processing capacity of 1,200 tons of plasma. This project will help the company expand its production scale and increase its market share

    Zhitong·
    SZ
    002880
    -0.19%
    Zhitong·
    SZ
    002880
    -0.19%
    © 2025 Longbridge｜Disclaimer